Regeneron Pharmaceuticals Inc (LTS:0R2M)
$ 827.21 -6.645 (-0.8%) Market Cap: 91.15 Bil Enterprise Value: 84.05 Bil PE Ratio: 20.53 PB Ratio: 3.11 GF Score: 93/100

Regeneron Pharmaceuticals Inc Oncology Investor Event ASH 2020 Transcript

Dec 07, 2020 / 09:30PM GMT
Release Date Price: $495.51 (+0.17%)
Operator

Hello. Thank you for holding, and welcome to the Regeneron Oncology Investor Event ASH 2020. (Operator Instructions) Please be advised that today's conference may be recorded. (Operator Instructions)

I would like to turn the call to the Head of Investor Relations, Mr. Justin Holko. Please go ahead.

Justin Holko
Regeneron Pharmaceuticals, Inc. - VP of IR

Welcome, everyone, to Regeneron's Oncology Hematology ASH 2020 webcast. Joining me on the call today are Dr. George Yancopoulos, Co-Founder, President and Chief Scientific Officer; Dr. David Weinreich, Senior Vice President and Head of Commercial and Clinical Development; Dr. Andres Sirulnik, Senior Vice President, Translational and Clinical Sciences Hematology; and Dr. Israel Lowy, Senior Vice President of Translational Sciences and Oncology.

After our prepared remarks, we will open the call for Q&A.

Before handing the call over to George, I would like to remind you that remarks made on today's call include forward-looking statements about Regeneron, including those relating to

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot